SCHEMBL1251498

SCHEMBL1251498

CS(=O)(=O)ON1CCCc2c1c(-c1cccnc1)n[nH]c2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.39
▸ ALPL P05186 1/20 0.38
▸ ACHE P22303 1/20 0.37
▸ PTGS2 P35354 2/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ CYP11B1 P15538 2/20 0.36
▸ CYP11B2 P19099 2/20 0.36
▸ PIM1 P11309 2/20 0.36
▸ BTK Q06187 1/20 0.36
▸ CHEK1 O14757 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ ALK Q9UM73 1/20 0.35
▸ MAP2K4 P45985 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249951 0.87 NPC1 (0.38) PARP1ROCK2LRRK2PDE4APDE4B
SCHEMBL1252377 0.82 PARP1 (0.39) PARP1CHEK1ROCK2ROCK1PDE4A
SCHEMBL1249990 0.81 PARP1 (0.41) PARP1PTGS2ROCK2ROCK1KMT2A
SCHEMBL1250090 0.81 NOTUM (0.37) PARP1PTGS2PTGS1LRRK2PDE4A
SCHEMBL1251282 0.80 PDE4A (0.37) PARP1ROCK2ROCK1PDE4APDE4B
SCHEMBL1251616 0.80 ROCK2 (0.38) PARP1ROCK2ROCK1MAP2K4PDE4A
SCHEMBL1252260 0.79 PARP1 (0.40) PARP1PDE4APDE4BPDE4CPDE4D
SCHEMBL1252649 0.78 PARP1 (0.40) PARP1ROCK2ROCK1PDE4APDE4B
SCHEMBL1252351 0.77 PDE4A (0.36) PARP1ROCK2ROCK1PDE4APDE4B
SCHEMBL1252655 0.76 PARP1 (0.52) PARP1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2281818-A1 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2011-02-09 — — EP disclosed
US-20080261947-A1 FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. 2008-10-23 — — US disclosed
US-7402580-B2 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 — — US disclosed
US-20050085476-A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 — — US disclosed
EP-1477175-A1 FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085476-A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient MUSK, RNASE1, DPYD PARP1 4/4885ALPL 1737/4885ACHE 63/4885
US-20080261947-A1 FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT MUSK, RNASE1, DPYD PARP1 4/4885ALPL 1882/4885ACHE 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback